Trinity Biotech (TRIB) Operating Income (2009 - 2024)

Trinity Biotech has disclosed Operating Income across 16 years of filings, most recently posting -$11.5 million for Q4 2024.

• In Q4 2024, Operating Income fell 204.66% year-over-year to -$11.5 million; the TTM figure through Dec 2024 stood at -$21.2 million (up 21.76% YoY), while the FY2025 annual figure was -$15.8 million, up 25.4% from the prior year.
• Operating Income came in at -$11.5 million for Q4 2024 at Trinity Biotech, down from -$2.6 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $9.1 million in Q3 2020 to a low of -$14.9 million in Q2 2023.
• Average Operating Income over 5 years is -$2.0 million, with a median of -$2.2 million recorded in 2022.
• Year-over-year, Operating Income jumped 581.55% in 2020 and slumped 1548.85% in 2022.
• Over 5 years, Operating Income stood at $9.1 million in 2020, then plunged by 93.79% to $563000.0 in 2021, then tumbled by 1548.85% to -$8.2 million in 2022, then soared by 53.67% to -$3.8 million in 2023, then sank by 204.66% to -$11.5 million in 2024.
• Per Business Quant data, the three most recent Operating Income figures were -$11.5 million in Q4 2024, -$2.6 million in Q3 2024, and -$4.1 million in Q2 2024.